|
|
|
| home > white papers > Points to Consider When Developing a TMF (Trial Master File) Strategy - Phlexglobal Ltd |
|
|
 WHITE PAPERS |
|
Phlexglobal Ltd
|
|
Points to Consider When Developing a TMF (Trial Master File) Strategy
|
|
Many organizations are currently outsourcing clinical trial activities
to one or more contract research organizations (CROs). This strategy
enables companies to leverage specialized expertise and take advantage
of flexible resourcing throughout the conduct of a clinical trial.
Outsourcing minimizes the costs of recruiting experts, building a team
and maintaining an infrastructure. However, it can also add complexity
as the organization looks to meets its compliance obligations regarding
clinical trial documentation.
The documentation referred to in
Article 15(5) of Directive 2001/20/EC as the trial master file shall
consist of essential documents, which enable both the conduct of a
clinical trial and the quality of the data produced to be evaluated.1
This essential study specific documentation is also known as the TMF. As
organizations try to minimize their reliance on paper files, the
electronic TMF (eTMF) has emerged. A current industry initiative to
standardize the organization of this content is known as the TMF
Reference Model. This model is helping standardization efforts across
paper and electronic systems.
As companies implement outsourcing
strategies, CROs and sponsor organizations look for a common foundation
on which to build their TMF capabilities. The following paper outlines
some of the challenges organizations face when outsourcing clinical
trial activities to multiple contract research organizations and a
strategy to facilitate partnering and management of trial information
between sponsors and CROs.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
PerkinElmer Introduces Next Generation, Automated Gas Chromatography Platform
WALTHAM, Mass.--(BUSINESS WIRE)--Jun. 21, 2022--
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating
for a healthier world, today launched the GC 2400™ Platform, an
advanced, automated gas chromatography (GC), headspace sampler and
GC/mass spectrometry (GC/MS) solution designed to help lab teams
simplify lab operations, drive precise results, and perform more
flexible monitoring.
More info >> |
|
 |
White Papers |
 |
|
Biosimilars In Emerging Markets: Is It A Level Playing Field?
PRA Health Sciences (PRA)
Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >> |
|
 |
Industry Events |
 |
Connect in Pharma
14-15 September 2022, Plaexpo, Geneva, Switzerland
The new event driving innovation for pharma and biopharma businesses,
Connect in Pharma will unite key players in Pharmaceutical and
Biopharmaceutical packaging and production in Geneva on 14 – 15
September 2022.
More info >> |
|
|
|
